Company news

AptarGroup, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Third Quarter 2026 Historical Financials

October 30, 2026

Aptar Reports Third Quarter 2026 Results

October 29, 2026

Aptar Increases Quarterly Dividend to $0.50 Per Share

October 29, 2026

Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection

October 27, 2026

Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery

October 26, 2026

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

October 22, 2026

Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

October 14, 2026

Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies

October 5, 2026

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

September 14, 2026

Aptar Pharma Expands Preservative Free Technology Production in Latin America

September 11, 2026

Aptar and Aceso Therapeutics Announce Collaboration to Advance Inhaled Antisense Oligonucleotide Therapy for Cystic Fibrosis

September 7, 2026

Aptar Reports Second Quarter 2026 Results

July 30, 2026

Aptar Named One of the World's Most Sustainable Companies by TIME for Third Consecutive Year

July 27, 2026

Aptar Pharma Announces GMP Certification at Nanopharm, Strengthening Its Integrated Pharma Services Offering

July 22, 2026

Aptar Beauty Launches Next-Generation Auto-Loading Dropper Technology for Easier, More Accurate Skincare Dosing

July 20, 2026

Aptar Pharma Launches Integrated System-Level Framework to Support Injectable Drug Development

July 17, 2026

Aptar Named Among Top 100 of America’s Best Companies by TIME

July 13, 2026

Aptar Releases 2025 Corporate Sustainability Report

June 18, 2026

Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year

June 2, 2026

Aptar Pharma Announces New Patent Applications and Preclinical Data Supporting Investigation of Intranasal and Pulmonary GLP-1 Delivery

May 28, 2026

Aptar Advances Sustainability Features in Luxury Packaging through Patented Reloadable Airless Innovation with Clarins

May 6, 2026

First Quarter 2026 Historical Financials

May 1, 2026

Aptar Reports First Quarter 2026 Results

April 30, 2026

Aptar Turns Beauty and Personal Care Products Upside Down with Inverted Lidless Dispensing Closures for Clean, Single‑Handed Dispensing

April 27, 2026

Aptar Recognized as One of America’s Climate Leaders by USA Today for the Fourth Consecutive Year

April 22, 2026

Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution

April 8, 2026

Global Cosmetic Dropper Market to Reach USD 1,855.9 Million by 2036 | Asia Pacific Leads Skincare Boom; AptarGroup

April 1, 2026

Global Pump and Dispenser Market to Reach USD 84.6 Billion by 2036 Led by North America and AptarGroup Inc. Innovation

March 27, 2026

Global Aerosol Valves Market to Reach USD 3.8 Billion by 2036 as Europe Leads and AptarGroup & LINDAL Expand Capacity

March 26, 2026

Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray

March 19, 2026

Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year

March 17, 2026

Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray

March 16, 2026

Bank of America 2026 Injectable Drug Packaging Virtual Field Trip

March 2, 2026

Bank of America 2026 Global Agriculture and Materials Conference

February 25, 2026

Fourth Quarter 2025 Historical Financials

February 6, 2026

Aptar Reports Fourth Quarter and Annual 2025 Results

February 5, 2026

Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details

January 22, 2026

Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment

January 21, 2026

Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate

January 13, 2026

Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™

January 12, 2026

Aptar Announces 2026 Quarterly Conference Call Dates

January 7, 2026

Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring

January 6, 2026

Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

January 5, 2026

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

December 17, 2025

Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year

December 4, 2025

Aptar Acquires Sommaplast, a Specialized Provider of Oral Dosing Pharma Packaging Solutions

December 1, 2025

Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025

November 11, 2025

Aptar Reports Third Quarter 2025 Results

October 30, 2025

Aptar Digital Health Announces FDA 510(k) Clearance for HeroTracker® Sense, a Connected Add-On Device for Metered-Dose Inhalers

October 16, 2025

Aptar Named Among Top 100 of the ‘World’s Top Companies for Women 2025’ by Forbes

October 15, 2025

Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.